Vivos Therapeutics Secures Extension for Critical $2.6M Financing Deadline
VVOS is trading near its 52-week low of $0.383 (13% above the low) on light trading volume (0.1× avg).
Summary
Vivos Therapeutics received an extension from its senior lender, Streeterville Capital, for a critical $2.6 million financing deadline, pushing it to August 31, 2026, and reaffirming a $4.5 million debt-to-equity conversion.
Key Events · Financing and Capital Events · VVOS
-
Financing Deadline Extended
The deadline for Vivos Therapeutics to complete a qualifying financing of at least $2.6 million has been extended from June 15, 2026, to August 31, 2026, following the company's failure to meet the original date.
-
Debt-to-Equity Conversion Reaffirmed
Streeterville Capital, the senior lender, reaffirmed its commitment to convert up to $4.5 million of outstanding debt into a combination of preferred and common stock, contingent on the company raising the $2.6 million financing.
-
Impact on Nasdaq Compliance
The extension is intended to provide Vivos Therapeutics more time to raise necessary equity, which is crucial for strengthening its stockholders' equity and maintaining compliance with Nasdaq listing standards, given its prior non-compliance notice.
Analysis · VVOS · Industrial Applications And Services
Vivos Therapeutics, a company facing significant financial distress, a 'going concern' warning, and Nasdaq delisting risk, failed to meet its June 15, 2026 deadline to secure $2.6 million in financing. This 8-K announces that its senior lender, Streeterville Capital, has granted an extension to August 31, 2026, and reaffirmed its commitment to convert up to $4.5 million of debt into equity once the financing is achieved. This extension is critical for the company's immediate survival and its efforts to comply with Nasdaq listing standards, preventing an immediate default or further financial deterioration.
At the time of this filing, VVOS was trading at $0.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.38 to $7.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.